BioRender is a private company building in scientific visualization software, founded in 2017. Investors last valued the company at $900M (post-money). No public ticker exists for the company.
1 valuation. The latest, $900M post-money, was set by the Strategic Investment / Employee Liquidity in Dec 2025.
Y CombinatorBioRender is a scientific figure and illustration software company founded in 2017 and headquartered in Canada. Scientists use it to build figures, flowcharts, protocols, and timelines with a library of over 50,000 icons, and the platform now applies AI to generate and edit custom figures in the same style.
More than 4 million scientists use BioRender, including researchers in Nobel-prize-winning labs and teams at all of the top 30 pharmaceutical companies. Founder Shiz Aoki started the company in 2017 after her medical illustration firm in Toronto could not keep up with demand from scientists.
Listed funds carry late-stage private names. A fund's latest schedule of investments shows whether it holds BioRender.
Often trade at a premium or discount to NAV.
Platforms match existing holders with buyers. BioRender availability at any moment is set by the holders.
High minimums, transfer approval, company right-of-first-refusal.
Valuations, rounds and IPO status for every company in the directory — BioRender included.
The closest scientific visualization software peers are on the competitors page.
The routes section explains what is realistically available for a company at this stage.
No. BioRender is a private company; its shares do not trade on a public exchange.
The last valuation is $900M (post-money, Dec 2025).
Perpetual markets for stocks, gold, indices and pre-IPO names — settled on-chain, no wallet-to-exchange transfers.
